Milestone Pharmaceuticals (NASDAQ:MIST) Shares Down 8.1% - Time to Sell?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report)'s stock price was down 8.1% on Thursday . The stock traded as low as $2.17 and last traded at $2.17. Approximately 985,561 shares changed hands during trading, an increase of 281% from the average daily volume of 258,721 shares. The stock had previously closed at $2.36.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Monday, October 14th.

Milestone Pharmaceuticals Price Performance

The stock's fifty day moving average is $1.84 and its 200-day moving average is $1.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The stock has a market capitalization of $117.32 million, a P/E ratio of -2.72 and a beta of 1.83.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. On average, equities analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds have recently modified their holdings of MIST. Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company's stock valued at $30,000 after buying an additional 10,000 shares during the period. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals during the third quarter valued at $46,000. Atria Investments Inc boosted its holdings in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company's stock valued at $61,000 after acquiring an additional 12,430 shares during the last quarter. BML Capital Management LLC increased its position in Milestone Pharmaceuticals by 3.0% in the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company's stock worth $1,727,000 after purchasing an additional 33,196 shares during the period. Finally, Lion Point Capital LP increased its position in Milestone Pharmaceuticals by 1.7% in the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company's stock worth $3,089,000 after purchasing an additional 40,000 shares during the period. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.